[1] WIERSINGA W J, VIRK H S, TORRES A G, et al. Melioidosis[J].Nat Rev Dis Primers,2018,4:17107.
[2] TOHICS L, MONTANA M, KOCH L, et al. A review of melioidosis cases imported into Eurpoe[J].Eur J Clin Microbiol Infect Dis,2019,38(8):1395-1408.
[3] BIRNIE E, VIRK H S, SAVELKOEL J, et al.Global burden of melioidosisin 2015: a systematic review and data synthesis[J]. Lancet Infect Dis,2019,19(8):892-902 .
[4] 李倩,毛旭虎.类鼻疽伯克霍尔德感染与免疫逃逸机制的研究进展[J]. 微生物与感染,2020,15(4):259-264.
[5] 吴华, 王旭明,黄东良.类鼻疽的临床和实验室研究进展[J]. 中华医学杂志,2018,98(42):3462-3464.
[6] HATCHER C I, MURUATO L A, TORRES A G. Recent advances in Burkholderia mallei and B.pseudomallei Research[J].Curr Trop Med Rep,2015,2(2):62-69.
[7] 支气管镜在急危重症临床应用专家共识组. 支气管镜在急危重症临床应用专家共识[J]. 中华急诊医学杂志,2016,25(5):568-572.
[8] MIMA T, SCHWEIZER H P.The BpeAB-OprB efflux pump of Burkholderia pseudornallei 1026b does not play a role in quorum sensing,virulence factor production or extrusion of aminoglycosides but is a broad-spectrum drug efflux system[J].Antimicrob Agents Chemother,2010,54(8):3113-3120.
[9] Clinical and Laboratory Standards Instiute.Methods for antimicrobial dilution and disk susceptibility testing for infrequently isolated or fastidious bacteria.3rd ed.CLSI guideline M45[R].CLSI document P60.Wayne,PA:CLSI,2015.
[10] LAWS T R,TAYLOR A W,RUSSELL P,et al. The treatment of melioidosis:is there a role for repurposed drugs? A proposal and review[J]. Exp Rev Anti Infect Therapy,2019,17(12):957-967.
[11] CHANTRATITA N, RHOLL D A, SIM B, et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei[J]. Proc Natl Acad Sci U S A, 2011, 108(41): 17165-17170. |
